ClinicalTrials.gg

Program

autogene cevumeran

Also written as “Autogene cevumeran”, “Autogene Cevumeran” and “RO7198457 intravenous (IV)”.

Its studies are mostly in Melanoma · Colorectal Neoplasms · Adenocarcinoma, led by 2 companies.

Furthest: phase 2, since Jan 7, 20195 company-led studies, 3 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche42 open or runningphase 2since Jan 7, 2019Sep 19, 2017Nov 10, 2027phase 2 · NCT06534983
BioNTech11 open or runningphase 2since Jul 20, 2020Jul 20, 2020Nov 2026phase 2 · NCT04486378
  • Named in Hoffmann-La Roche’s own pipeline as RG6180 autogene cevumeran (BioNTech), phase 2, as of Oct 22, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 19, 2017First study: phase 1 study in MelanomaNew to Hoffmann-La RocheHoffmann-La Roche · NCT03289962 · 273 enrolled · United States, Belgium, Canada and more
  2. Jan 7, 2019Phase 2 study in Advanced MelanomaHoffmann-La Roche · NCT03815058 · 131 enrolled · United States, Australia, Belgium and more
  3. Jul 20, 2020BioNTech's first study: phase 2 study in Colorectal NeoplasmsNew to BioNTechBioNTech · NCT04486378 · 327 enrolled · United States, Belgium, Canada and more
  4. Jul 21, 2023Phase 2 study in AdenocarcinomaHoffmann-La Roche · NCT05968326 · 260 enrolled · United States, Belgium, Canada and more
  5. Jul 30, 2024Phase 2 study in Muscle-invasive Urothelial CarcinomaHoffmann-La Roche · NCT06534983 · 62 enrolled · United States, Argentina, Australia and more

Ahead

  1. Nov 2026Primary completion: phase 2 study in Colorectal NeoplasmsBioNTech · NCT04486378
  2. Nov 10, 2027Primary completion: phase 2 study in Muscle-invasive Urothelial CarcinomaHoffmann-La Roche · NCT06534983
  3. Jan 1, 2031Primary completion: phase 2 study in AdenocarcinomaHoffmann-La Roche · NCT05968326

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“An mRNA-based individualized, therapeutic cancer vaccine targeting an unspecified amount of tumor-associated antigens (TAAs) that are specifically expressed in the patient's cancer, with potential immunostimulatory and antineoplastic activities. Upon administration, autogene cevumeran is taken up…”NCIt, read by Claude

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06534983Muscle-invasive Urothelial Carcinoma · United States, Argentina, Australia and more2Active, not recruitingHoffmann-La RocheNov 10, 202762
NCT05968326Adenocarcinoma · United States, Belgium, Canada and more2Active, not recruitingHoffmann-La RocheJan 1, 2031260
NCT04486378Colorectal Neoplasms · United States, Belgium, Canada and more2Active, not recruitingBioNTechNov 2026327
NCT03815058Advanced Melanoma · United States, Australia, Belgium and more2CompletedHoffmann-La RocheJan 21, 2025131
NCT03289962Melanoma · United States, Belgium, Canada and more1CompletedHoffmann-La RocheJul 1, 2025273

How it is read

Names in the registry

  • “Autogene cevumeran”, 3 entries
  • “Autogene Cevumeran”, 1 entry
  • “RO7198457 intravenous (IV)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.